Who is sponsoring NCT03051932?

NCT03051932 is sponsored by The University of Texas Medical Branch, Galveston.

What drugs are being tested in NCT03051932?

Interventions in NCT03051932: Ofiramev® (IV Acetaminophen), Placebo IV administration.

What condition does NCT03051932 study?

NCT03051932 studies Post-thoracotomy Pain Syndrome.

Is NCT03051932 still recruiting?

NCT03051932 is currently withdrawn. Last updated 5 February 2019.

Last reviewed 2019-02-05 · How we verify

NCT03051932: IVTylenol

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Intravenous Acetaminophen in Patients Undergoing Thoracoscopic Surgery

Withdrawn NA Last updated 5 February 2019

What this trial tests

NA trial testing Ofiramev® (IV Acetaminophen) in Post-thoracotomy Pain Syndrome. Withdrawn.

Timeline

1 June 2018

Primary endpoint
1 June 2019

1 June 2019

Quick facts

Lead sponsor	The University of Texas Medical Branch, Galveston
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Start date	1 June 2018
Primary completion	1 June 2019
Estimated completion	1 June 2019

Drugs / interventions tested

Ofiramev® (IV Acetaminophen) — full drug profile →
Placebo IV administration — full drug profile →

Conditions studied

Post-thoracotomy Pain Syndrome — all drugs for Post-thoracotomy Pain Syndrome →

Sponsor

The University of Texas Medical Branch, Galveston

Who can join

Adults 18 to 99, any sex, with Post-thoracotomy Pain Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, randomized, double-blind, placebo-controlled trial. A total of 100 patients, 50 per treatment arm, undergoing minimally invasive thoracic surgery will be randomized 1:1 across 2 treatment arms: Ofiramev® (acetaminophen) injection 1,000 mg (100 mL) plus patient-controlled analgesia (PCA) and 100 mL placebo plus PCA.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other The University of Texas Medical Branch, Galveston trials

Trials by the same sponsor.

NCT04095260 — Identification of Neuromusculoskeletal Variables Associated With Injury Risk and Performance in High School Athletes. · not yet recruiting
NCT06800092 — Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment · Phase 2, PHASE3 · not yet recruiting
NCT07337915 — Improving Sleep In Midlife Women · NA · recruiting
NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
NCT07087743 — Virtual Reality-Integrated Propulsion Feedback for Stroke Rehab · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03051932 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Medical Branch, Galveston
Last refreshed: 5 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03051932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing